DARAXONRASIB (RMC-6236), DOCETAXEL, DARAXONRASIB (RMC-6236)
RMC-6236-301
Phase 3 small_molecule active
Quick answer
DARAXONRASIB (RMC-6236), DOCETAXEL, DARAXONRASIB (RMC-6236) for non-small cell lung cancer is a Phase 3 program (small_molecule) at Revolution Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Revolution Medicines
- Indication
- non-small cell lung cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active